We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BVT:JSEBidvest Group Limited Analysis

Data as of 2026-03-14 - not real-time

ZAC 22,850.00

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

The Bidvest Group trades at ZAc 22,850, which sits about 15% above its DCF‑derived fair value of ZAc 19,889, signaling a potential overvaluation despite a solid dividend yield of 4.33% and a modest payout ratio of 52%. Technical gauges show the stock is below its 20‑day (ZAc 24,223) and 50‑day (ZAc 24,227) moving averages, with an RSI of 34.6 indicating oversold conditions, while a bearish MACD histogram reinforces short‑term downside pressure. Nevertheless, the company’s low beta of 0.37 and increasing volume suggest limited market‑wide volatility, and its diversified industrial footprint provides a stable earnings base.
Fundamentally, Bidvest delivers a PE of 12.97 versus an industry average of 29.1, a healthy ROE of 15.4%, and free cash flow that comfortably covers its dividend. The combination of a strong dividend, low valuation multiples, and resilient cash generation supports a value‑oriented investment case, though the price premium to intrinsic value warrants caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI near oversold territory suggesting limited upside
  • Bearish MACD histogram indicating continued pressure
  • Price trading below short‑term moving averages

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • PE well below industry average offering valuation cushion
  • Sustainable dividend yield of 4.33% with healthy cash flow
  • Low beta reducing exposure to broader market swings

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Diversified conglomerate model providing resilient earnings
  • Strong ROE and free cash flow supporting dividend continuity
  • Potential price correction toward DCF fair value offering upside

Key Metrics & Analysis

Financial Health

Revenue Growth3.70%
Profit Margin4.72%
P/E Ratio13.0
ROE15.38%
ROA6.10%
Debt/Equity102.11
P/B Ratio197.9
Op. Cash FlowZAC11.1B
Free Cash FlowZAC6.7B
Industry P/E29.1

Technical Analysis

TrendNeutral
RSI34.6
SupportZAC 20,650.00
ResistanceZAC 26,000.00
MA 20ZAC 24,223.65
MA 50ZAC 24,226.68
MA 200ZAC 23,263.77
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair ValueZAC 19,889.81
Target PriceZAC 29,955.83
Upside/Downside31.10%
GradeOvervalued
TypeValue
Dividend Yield4.33%

Risk Assessment

Beta0.37
Volatility25.67%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.